From the Research
The Nestroft test is a valuable screening tool for beta-thalassemia trait, with a sensitivity of 84.21% and specificity of 96.25%, and should be used as a cost-effective mass screening tool in resource-limited settings, followed by confirmation with HPLC or hemoglobin electrophoresis. The test involves mixing a drop of blood with 0.36% saline solution and observing for hemolysis after 30 minutes, with turbidity or cloudiness in the solution indicating thalassemia trait carriers 1. The Nestroft test is particularly useful in regions with high thalassemia prevalence, as it requires minimal equipment and training. However, clinicians should be aware that false positives can occur in other microcytic anemias like iron deficiency.
Some of the key benefits of the Nestroft test include:
- Cost-effectiveness
- Simplicity of the test
- Minimal equipment required
- Valuable in resource-limited settings
- High sensitivity and specificity
However, the test also has some limitations, including:
- False positives can occur in other microcytic anemias
- Not definitive and requires confirmation with HPLC or hemoglobin electrophoresis
- May not be suitable for all populations, particularly those with low thalassemia prevalence.
Overall, the Nestroft test is a useful screening tool for beta-thalassemia trait, particularly in resource-limited settings, and should be used in conjunction with other diagnostic tests to confirm the diagnosis 1.